Breast cancer treatments, including many chemotherapeutic agents and aromatase inhibitors, increase the risk of osteoporosis, as do many common comorbidities such as increasing age, genetic factors, lifestyle factors, and endocrine disorders. Here, CYP19A1 is linked to breast cancer.